http://orcid.org/0000-0001-5935-4098
References
- Delattre O. Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert I, de Jong P, Rouleau G, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359:162–165.
- Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: Current status and outlook for the future. Med Pediatric Oncol. 2003;40:276–287.
- Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, et al. EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. Nature. 2018;555:387–391.
- Ljungman M, Zhang F. Blockage of RNA polymerase as a possible trigger for u.v. light-induced apoptosis. Oncogene. 1996;13:823–831.
- Krum SA, Miranda GA, Lin C, Lane TF. BRCA1 Associates with Processive RNA Polymerase II. J Biol Chem. 2003;278:52012–52020.
- Brenner JC, Feng FY, Han S, Patel S, Goyal SV, Bou-Maroun LM, Liu M, Lonigro R, Prensner JR, Tomlins SA, et al. PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma. Cancer Research. 2012;72:1608–1613.
- Vormoor B, Curtin, N. J. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma. Curr Opin Oncol. 2014;26:428–433.
- Paronetto MP, Miñana B, Valcárcel J. The Ewing Sarcoma protein regulates DNA damage-induced alternative splicing. Mol Cell. 2011;43:353–368.
- Aguilera A, Garcia-Muse T. R loops: from transcription byproducts to threats to genome stability. Mol Cell. 2012;46:115–124.
- Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts S, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–218.